{"id":7127,"date":"2020-07-07T06:34:30","date_gmt":"2020-07-07T13:34:30","guid":{"rendered":"https:\/\/2020dev.rakuten-med.com\/?p=7127"},"modified":"2022-04-19T21:26:18","modified_gmt":"2022-04-20T04:26:18","slug":"rakuten-medical-closes-deal-with-merck-kgaa-darmstadt-germany-to-receive-cetuximab-for-production-of-rakuten-medicals-asp-1929-antibody-drug-conjugate","status":"publish","type":"press_releases","link":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/","title":{"rendered":"Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate"},"content":{"rendered":"

Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt,\u00a0Germany<\/span>\u00a0under which Merck KGaA,\u00a0<\/b>Darmstadt, Germany will provide cetuximab to Rakuten Medical for its ASP-1929 program. Rakuten Medical uses cetuximab in an intermediate form as the antibody component in its product candidate ASP-1929, an investigational antibody-dye conjugate being studied for the treatment of recurrent, locoregional head and neck cancers. Under this agreement, Rakuten Medical may use cetuximab to produce ASP-1929 for clinical trials and commercial sales. Read more…<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt,\u00a0Germany\u00a0under which Merck KGaA,\u00a0Darmstadt, Germany […]<\/p>\n","protected":false},"author":4,"featured_media":0,"template":"","meta":{"_acf_changed":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"class_list":{"0":"post-7127","1":"press_releases","2":"type-press_releases","3":"status-publish","5":"entry"},"yoast_head":"\nRakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate - Rakuten Medical - To conquer cancer.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate - Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:description\" content=\"Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt,\u00a0Germany\u00a0under which Merck KGaA,\u00a0Darmstadt, Germany […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/\" \/>\n<meta property=\"og:site_name\" content=\"Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-20T04:26:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2020\\\/07\\\/07\\\/7127\\\/\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2020\\\/07\\\/07\\\/7127\\\/\",\"name\":\"Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate - Rakuten Medical - To conquer cancer.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\"},\"datePublished\":\"2020-07-07T13:34:30+00:00\",\"dateModified\":\"2022-04-20T04:26:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2020\\\/07\\\/07\\\/7127\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2020\\\/07\\\/07\\\/7127\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2020\\\/07\\\/07\\\/7127\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\",\"name\":\"Rakuten Medical - To conquer cancer.\",\"description\":\"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate - Rakuten Medical - To conquer cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/","og_locale":"en_US","og_type":"article","og_title":"Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate - Rakuten Medical - To conquer cancer.","og_description":"Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt,\u00a0Germany\u00a0under which Merck KGaA,\u00a0Darmstadt, Germany […]","og_url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/","og_site_name":"Rakuten Medical - To conquer cancer.","article_modified_time":"2022-04-20T04:26:18+00:00","og_image":[{"width":1500,"height":900,"url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png","type":"image\/png"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/","url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/","name":"Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate - Rakuten Medical - To conquer cancer.","isPartOf":{"@id":"https:\/\/rakuten-med.com\/us\/#website"},"datePublished":"2020-07-07T13:34:30+00:00","dateModified":"2022-04-20T04:26:18+00:00","breadcrumb":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2020\/07\/07\/7127\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rakuten-med.com\/us\/"},{"@type":"ListItem","position":2,"name":"Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate"}]},{"@type":"WebSite","@id":"https:\/\/rakuten-med.com\/us\/#website","url":"https:\/\/rakuten-med.com\/us\/","name":"Rakuten Medical - To conquer cancer.","description":"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rakuten-med.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases\/7127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/types\/press_releases"}],"author":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/users\/4"}],"wp:attachment":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media?parent=7127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}